Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle (Q36118431)

12 August 2017

1 reference

title

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle (English)

1 reference

12 August 2017

Herbert B Newton

1

1 reference

12 August 2017

1 April 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

2

1 reference

12 August 2017

355-378

1 reference

Current epidemiological trends and surveillance issues in brain tumors

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Chemotherapy for the treatment of metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Tumor suppressor genes and cancer of the human nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Molecular pathways in the formation of gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis, cancer and the p53 tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The cellular response to p53: the decision between life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis. Its significance in cancer and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis: cell death in tissue regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Mechanisms and Functions of Cell Death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Cell death mechanisms and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis and caspases in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Mammalian caspases: structure, activation, substrates, and functions during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Caspase structure, proteolytic substrates, and function during apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The role of p53 in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Regulation of p53 downstream genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

A novel form of Epstein-Barr virus latency in normal B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

21 January 2018

The Bcl-2 protein family

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

BCL-2 family members and the mitochondria in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The mitochondrion in cell death control: certainties and incognita

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis by death factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Death receptors: signaling and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Altered nuclear localization of bax protein in BCNU-resistant glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Overexpression of bax in human glioma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The prognostic influence of bcl-2 in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Bcl-2 expression in higher-grade human glioma: a clinical and experimental study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

APO2 ligand: a novel lethal weapon against malignant glioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Expression of TRAIL and its receptors in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Quantitatively determined survivin expression levels are of prognostic value in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Transcriptional expression of survivin and its splice variants in brain tumors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Analysis of human transcriptomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Therapeutic exploitation of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis and cancer drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

From bench to clinic with apoptosis-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Apoptosis as a novel target for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The triterpenoid CDDO induces apoptosis in refractory CLL B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Integration of the pRB and p53 cell cycle control pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Current concepts in neuro-oncology: the cell cycle--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The cell cycle: accelerators, brakes, and checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

What is the restriction point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Creative blocks: cell-cycle checkpoints and feedback controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Principles of CDK regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Crystal structure of cyclin-dependent kinase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The decision to enter mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Inhibitors of mammalian G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Targets of cyclin-dependent protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The retinoblastoma protein and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

DNA tumor virus transforming proteins and the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The anaphase-promoting complex: proteolysis in mitosis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Substrate recognition by the Cdc20 and Cdh1 components of the anaphase-promoting complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Expression of the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Comparison of cytologic composition with microfluorometric DNA analysis of the glioblastoma multiforme and anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Histological grading, DNA content, cell proliferation and survival of patients with astroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Prognostic relevance of DNA flow cytometry in oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Histopathologic grading and DNA ploidy in relation to survival among 206 adult astrocytic tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Cyclin D1 in astrocytic tumours: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Immunohistochemical analysis of cyclin A in astrocytic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Delivery of cell cycle genes to block astrocytoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Anticancer drug targets: cell cycle and checkpoint control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

CDK inhibition and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Complexities in the development of cyclin-dependent kinase inhibitor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Proteasome inhibition: a new strategy in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Proteasome inhibition: a novel approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Clinical update: proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The role of proteasome inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Proteasome-dependent degradation of p27/kip1 in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Development of the proteasome inhibitor Velcade (Bortezomib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Inhibition of DNA synthesis in human gliomas by roscovitine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Discovering novel chemotherapeutic drugs for the third millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

The impact of genomic and proteomic technologies on the development of new cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Microarrays as cancer keys: an array of possibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

Application of microarrays to neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.355

21 January 2018

Identifiers

DOI

10.1586/14737140.5.2.355

1 reference

release_zf7voq4sezhxxo7is7uyx7smj4

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zf7voq4sezhxxo7is7uyx7smj4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15877531

1 reference

PubMed ID

15877531